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Abstract: Backgorund: Acinetobacter baumannii is often referred to as the “Gram-negative methicillin-resistant 
Staphylococcus aureus”, because it is frequently resistant to antibiotics. Clonal outbreaks of carbapenem-resistant and 
OXA-23–producing A. baumannii have been reported worldwide. Aim: The goal of this study was to promote the 
phenomenon of disbalance in endemic hospital ECO system which included increase of carbapenemase-resistant 
Acinetobacter baumanii on account of reduction of MRSA rate in surgical ICU and it’s clonal relatedness as well as the 
specific precautions. Material nad Methods: Computer database from 1994 – 2012 from surgical ICU patients in the 
Clinical Center Skopje was used as basic material for this study. Comparative study indicated 2007/8 as a break point 
period in which almost a twofold decrease of MRSA rates (from over 80% to 45%) versus increased rates of Acinetobacter 
baumanii (from 29% to 40%) was observed. In 2011 the very first eight strains of carbapenem resistant (resistant to 
imipenem and meropenem) A. baumannii, were observed. Disc diffusion and VITEK were used for antibiotic susceptibility 
testing. Resultes: Three distinct strains were detected by PFEGE and were designated as UKIM01AC-1 (5 strains), 
UKIM01AC-2 (two strains) and 642/2 (one strain). UKIM01AC-1 representatives were PCR positive for bla (OXA-23-
like), in addition to the bla (OXA- 51-like) gene which is intrinsic in Acinetobacter baumannii. All isolated strains 
belonged to European clone II lineage. Conclusion: This clone dispersed very fast in 2012 and achieved the rate of 61.9%. 
This implicated changes in infection control precautions. 
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1. Background
Acinetobacter baumannii is often referred to as the“Gram-
negative methicillin-resistant Staphylococcus aureus ”, 
because it is frequently resistant to antibiotics. [1,2,3] 
The epidemiologies of the two microbial species are very 
different and therefore, it is questionable whether the same 
control measures can be applied to the two pathogens. 
MRSA is primarily spread from person-to-person, whereas 
Acinetobacter infections often have an environmental source 
or reservoir. Allen and Green concluded that widespread 
aerial dissemination of Acinetobacter spp. occurred and this 
partly contributed to the environmental reservoir. 
Referring to Allen and Green’s study, Das et al. [4] 
hypothesised that heavily contaminated bed curtains, when 
moved would promote the airborne spread of Acinetobacter 
spp. Weernink et al. [5] investigated the airborne dispersal of 
Acinetobacter baumanii from patient’s pillows. Using settle 
plates they found aerial dissemination from feather pillows, 
but not from synthetic pillows. 
Numerous investigators have demonstrated the relative 
ease with which the clinical environment can become 
contaminated with pathogenic Acinetobacter species. 
Dissemination by airborne or other routes can seed 
environmental reservoirs which either can start [6] or 
prolong outbreaks [7,8]. In institutions where outbreaks 
occur in ICUs, a common contaminated object in the 
environment can often be identified as the source. In contrast, 
in other hospitals, where epidemic infections have become 
endemic, the clinical and microbiological epidemiology of 
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these infections often remains obscure. Allen and Green [4] 
were the first to suggest airborne dissemination of 
Acinetobacter-carrying particles. Investigating an outbreak 
of multiply-antibiotic resistant Acinetobacter anitratus in an 
ICU, a medical ward and three neurosurgical wards, they 
cultured the outbreak organism from 16 of 82 settle plates. 
Interestingly, all the positive plates were located within 3m 
of the colonised patients. 
There are studies showing the geographically widespread 
occurrence of multidrug-resistant A. baumannii strains, 
which suggested a clonal relatedness of these strains. [9, 10] 
Three international A. baumannii clones associated with 
multidrug resistance (European clones I, II, and III) have 
been reported). 
Clonal outbreaks of carbapenem-resistant and OXA-23–
producing A. baumannii have been reported in many 
countries, such as Bulgaria, People’s Republic of China, 
Brazil, Iraq, Afghanistan, Spain [9,10,11]. 
2. Aim of the Study 
The goal of this study was to promote the phenomenon 
of disbalance in endemic hospital ECO system which 
included increase of carbapenemase-resistant 
Acinetobacter baumanii on account of reduction of 
MRSA rate in surgical ICU, by long-term monitoring,  and 
the track whether disseminated strains of Acinetobacter 
were relevant. The final goal of this investigation was to 
promote specific precautions in order to minimise the 
acquisition and spread of these emerging infections that are 
difficult to treat.  
3. Methodology 
Comparative monitoring from database has indicated that 
there is a connection among emerging isolation of MDR 
Acinetobacter baumannii versus declination of MRSA 
isolates, both originating from surgical ICU patients  in a 
long period of time. 
2007/8 has been indicated as a break point period in 
which there was decriese of MRSA rates (from over 80% to 
45%) versus increased rates of Acinetobacter baumanii 
isolation (from 29% to 40%) [Fig 1]. 
 
Figure 1. Acinetobacter isolation in ICU in the period of 1991/1994, 
2006/2007 and 2010/2012 year  
Table 1. Significance of isolation ratio for Acinetobacter isolates  
(1991/1994, 2006/2007 and 2010/2012 year)  
Period Student – t test of proportions 
1991 / 1994 – 2006 / 2007 p = 0,0020 ( Sign.) 
1991 / 1994 – 2010 / 2012 p = 0,0018 (Sign.) 
2006 / 2007 – 2010 / 2012 p = 0,7613 (N.Sign.) 
Acinetobacter baumanii is an important nosocomial 
pathogen in this Unit. In the period from 1991-1994 the 
rate of isolation was 29% (N=363). It significantly arised in 
the period from 2006-2007 to 40% (N=355) and reflect this 
level in the next 5 years. On the other hand, MRSA became 
an important isolate in ICU in 1997 with over 80% rates 
sustaining percentage during the next decade, until 2007 
when it was almost twice reduced. [Fig 2]. 
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Fig 2. MRSA isolation in ICU in the period 1994-2008 
Amikacin used to be a drug of choice in treatment of 
Acinetobacter baumanii infections during this long period 
of time, which has resulted in significant increasing 
(p=0,0017) the resistance to this antibiotic in the period 
from 2005-2007 [Fig 3].  
 
Figure 3. Resistance of Acinetobacter isolates to amikacin and 
introduction of carbapenems (imipenem) 
That is why carbapenems, firstly imipenem and later on 
meropenem, were  involved in therapy in the early 2000s. 
3.1. Design of the Study 
Antibiotic resistance among Acinetobacter baumanii has 
been observed in 3 periods of time: early period 1990 – 2004, 
middle period 2005-2007 and recent period 2010-2012. 
Strains of Acinetobacter baumanii originated from 
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entubated patients in the surgical ICU. They were identified 
by classical microbiological procedure and confirmed by 
automatic VITEK technique). Susceptibility patterns to β-
lactam antimicrobial drugs were determined by using a 
standard disk diffusion method according to published 
standards. Then strains of interest were determined   by the 
agar dilution method, according to established NCCLS and 
confirmed by automatic VITEK test. Observation included 
3 routinely used antibiotics, amikacin, imipenem and 
meropenem, since the observed strains were MDR. 
Student
’
s t-test of proportion was the epidemiological 
tool used in order to monitor the changes in resistance to 
carbapenems, from year to year, in the middle period and in 
the recent period of observation. 
Eight strains of Acinetobacter  baumanii were recognized 
to be  resistant to both routinely used carbapenems 
(imipenem and meropenem) in the recent period, that was 
not the case with all other strains isolated ever before. 
Clonal relatedness of these strains was assessed by pulsed-
field gel electrophoresis (PFGE) and multilocus sequence 
typing in Health Protection Agency London by kindly 
collaboration with Prof Dr T.Pitt and Dr.Jane Turtone.[1,12] 
Presence of the blaOXA-23 gene was screened by PCR using 
specific primers (OXA-23-A 5′-
GGAATTCCATGAATAAATATTTTACTTGC-3′ and OXA-
23-B 5′-CGGGATCCCGTTAAATAATATTCAGGTC-3′). 
Further PCR detection of these clones was performed in 
Institute of microbiology Skopje. 
4. Results 
4.1. Acinetobacter Baumanii Ratio in Surgical ICU in the 
21 Year Period 
The rates of Acinetobacter baumanii isolation in the 21 
year period of observation in the surgical ICU, have 
showan a significant increas in the middle period (2006/7) 
with 40% (0,0018) rate of isolation.  This trend of isolation 
has been observed in next the “recent period” (38,5%), 
(2010-2012). [Fig 1].  
The rate of isolation of MRSA as predominant pathogen in 
CARIC with 80% ratio has been found over ten year-period, 
until 2007/8, when it suddenly decreased to 40% [Fig 2]. 
4.2. Antibiotic Susceptibility 
Comparison of antibiotic resistance to amikacin among the 
three investigated periods showed a significant ramp from 
30% to 80% (p=0.00001) in the middle period (2006/2007) 
and almost complete (97%) resistance in the “recent period” 
(2010-2012)  among 208 isolates of Acinetobacter. [Tab 1] 
These data coincide with the introduction of imipenem in 
the treatment of surgical ICU patients, and registration the first 
imipenem-resistant strains (10%) in the same period [Fig 3]. 
Ramps of resistance to imipenem from year to year, pointed 
a significant increase of imipenem-resisitance in 2007. [Fig 4]. 
 
Figure 4. Dynamic of the resistance of Acinetobacter spp. to imipenem in 
the middle period – 2005/2007  
Trend of spreading resistance to imipenem reached 73% 
(p=0,00001) in the “recent period” (2010-12) [Fig 5]. 
 
Fig 5. Imipenem and meropenem resistance of Acinetobacter baumanii in 
2010/2012 
According to Student
”
s t-test of proportion comparing 
2011 and 2010, there was a significant  (p = 0,0003) 
elevation of resistance to imipenem, as well as to 
meropenem (p=0,00001) (from 33% to 60% to Imipenem, 
and from 19,5% to 66% for meropenem). 
This trend was also observed in the first semester of 
2012, but it was still not significant in 2011 for imipenem  
(p-0,2010) as well as  for meropenem (p=0,2598) [Fig 5]. 
According to the data provided by the supplying service 
in the Surgery clinic, the use of relevant antibiotics in 2012 
versus 2011 displayed 59% increase for meropenem 
(370amp. vs 180) and 40 % decrease for imipenem (1010 
amp. vs 2465 amp). 
4.3. Molecular Analysis of Resistant Strains 
Carbapenem-resistant Acinetobacter baumanii strains 
(resistant to both carbapenems) were isolated in 2011 by 
PFEGE analysis, and were similar in dendograms. Five 
strains had identical dendogram and were designated as 
UKIMAC1, 2 other similar strains designated as 
UKIMAC2 and only one unique strain [Tab 2]. 
Tab 2. PCR recognition of carbapenemase genes 
Designition of 
test strains 
Bla(OXA 
58 like) 
Bla(OXA 
23 like) 
Bla(OXA 
51 like) 
Bla 
(OXA 40 
like) 
UKIM01 AC-
1 (N=5) 
negative positive positive negative 
UKIM01AC-2 negative negative positive negative 
642/2 unique negative negative positive negative 
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PFGE analysis and random amplified polymorphic DNA 
(RAPD) generated by arbitrarily primed polymerase chain 
reaction of these eight isolates indicated 2 closely related 
genotypes (2 clones). 
The OXA-23-producing isolates belonged to all 
genotypes. The presence of MDR OXA-23-producing A. 
baumannii in ICU has emphased the need to control the use 
of carbapenems. 
5. Discussion 
Continious monitoring is the basic tool in control of HAI, 
because it provides plenty of data about what happens in 
hospital ECO system, including appearance of MDR starins 
among endemic isolates and according to Rampell, changes 
in balance in hospital ECO system. 
By long-term monitoring Acinetobacter baumanii has 
been confirmed as an important nosocomial pathogen in 
CARIC in the period 1991-1994, but it was increased in the 
period of 2007/8 - 2012, on account of MRSA. Similar 
findig for the same period of time, were refered from the 
investigation in some other countries such as Brazil or 
Taiwan [17,18]. 
The comparative study indicated significant changes in 
EKO system in 2007/8 in  investigated ICU. MRSA rates 
were almost double reduced and on the other side, rates of 
Acinetobacter baumanii significantly increased. [13] 
Considering many differences in epidemiological 
characteristies of these two microorganisms, it was 
assumed that global or local conditions in the unit have 
been changed and/ it can be conetcet with the global 
changes in the climate [19,20].  Therefore Acinetobacter 
isolates became an important problem in this Unit, 
especially when carbapenem resistance was noticed in 2011 
among eight strains which had been nonsusceptible to all 
other antibiotics tested by the agar dilution method. 
All isolates of Acinetobacter were nonsusceptible to all 
of the antibiotics tested by the agar dilution method except 
amikacin until 2007  when resistance achieved 80%. After 
that imipenem was involved as alteranative antibiotic 
therapy. In the next 5 years resistance among acinetobacters 
was spread very fast, almost completely to aminoglikozide 
(93%) and very high to imipenem (73%). Since therapeutic 
choice of Acinetobacter infections was small, meropenem 
was involved uncontrolled in therapeutic routine practice 
[Tab3]. 
Table 3. Use of carbapenems in ICU for period 2011-2012  
 Ampulas used in 2011 Ampulas used in 2012 
meropenem 180 370 
imipenem 2465 1010 
gentamicin 270 380 
This led to sudden development of meropenem-resistance. 
Among eight carbapenem resistant Acinetobacter baumanii 
tested representatives three distinct strains were detected by 
PFEGE. Five of them could possible belong to the same 
source – type UKIM01AC-1 and another two were 
connected - UKIM01AC 2. All representatives of 
UKIM01AC-1 were PCR positive for bla (OXA-23-like), in 
addition to the bla (OXA- 51-like) gene, which was intrinsic 
in Acinetobacter baumannii. All isolated strains belonged to 
European clone II lineage. [14], although there are data for 
A.baumanii isolates positive for bla (OXA-23-like) on 
american continent [17],  This clone dispersed very fast in 
2012 and achieved the rate of 61,9% (N=84).  
6. Conclusion 
Carbapenem resistant Acinetobacter baumanii (European) 
clone II, became significant pathogen in CARIC, replacing 
MRSA which was predominant cause of infections in over 
ten years period of time. This MDR clone expressed big 
capacity for intra/inter-hospital dissemination of the clone, 
which was confirmed by literature data and was due to 
unrational antibiotic usage in CARIC.  
The new situation in this hospital ECO system indicated 
revision of hospital control strategies and applying new 
specific precautions. It was recommended: strong artificial 
control of air humidity, negative pressure in the critical 
room, proper care for bed-linen, replacement cotton with 
synthetic pillow, proper laundry of bed-linen, removal of 
mattress (once being Acineto-positive). Strong monitoring 
should be conduct over effect of recommended precautions 
for the following period of time. 
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